<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04156009</url>
  </required_header>
  <id_info>
    <org_study_id>19-06020284</org_study_id>
    <nct_id>NCT04156009</nct_id>
  </id_info>
  <brief_title>Lavender Aromatherapy Spine Procedure Study</brief_title>
  <official_title>Aromatherapy for Procedural Anxiety in Pain Management and Interventional Spine Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient anxiety prior to invasive procedures poses a significant barrier to successful
      treatment if not well-managed. The purpose of this study is to evaluate lavender
      aromatherapy, a non-sedating alternative, to reduce anxiety prior to interventional spinal
      procedures.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 29, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>For the treatment group, the aromatherapy tablets will be activated for max aromatherapy. For the control group, the tablets will not be activated and will be devoid of scent. For both groups, the tablet will be wrapped in masking tape to maintain the blind for subjects.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Subjects' Anxiety State as measured by the State Trait Anxiety Inventory (STAI-6)</measure>
    <time_frame>Administered within 30 minutes before and 30 minutes after intervention</time_frame>
    <description>The STAI-6 is a six-item assessment of state anxiety. Each item is assessed on a four-point Likert scale. Scores on the STAI-6 range from 6-24, with a higher score indicating greater state anxiety.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Vasovagal Events during Standard of Care Spine Procedure</measure>
    <time_frame>Assessed within 30 minutes following the standard of care spine procedure</time_frame>
    <description>All vasovagal events that occur during the standard of care spine procedure will be recorded and reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Aborted Standard of Care Spine Procedures</measure>
    <time_frame>Assessed within 30 minutes following standard of care spine procedure completion or abortion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Spine Injuries and Disorders</condition>
  <condition>Pain, Back</condition>
  <arm_group>
    <arm_group_label>Treatment (+aromatherapy) group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (-aromatherapy) group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Activated Lavender Elequil aromatabs® (#372)</intervention_name>
    <description>Activated Lavender aromatherapy tablets wrapped in tape</description>
    <arm_group_label>Treatment (+aromatherapy) group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Unactivated Lavender Elequil aromatabs® (#372)</intervention_name>
    <description>Unactivated Lavender aromatherapy tablets wrapped in tape</description>
    <arm_group_label>Control (-aromatherapy) group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females between 18-85 years old

          2. Scheduled for one of the following procedures on the day of consent:

               1. Epidural steroid injection (ESI)

               2. Medial branch block (MBB)

               3. Radiofrequency ablation (RFA)

          3. Able to provide informed consent

        Exclusion Criteria:

          1. History of anxiety disorder

          2. Currently on anxiolytic therapy

          3. Poor sense of smell

          4. Allergy/aversion to aromatherapy

          5. Non-English speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaspal R Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Cornell Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aromatherapy</keyword>
  <keyword>lavender</keyword>
  <keyword>anxiety</keyword>
  <keyword>spine intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Beginning 3 months and ending 5 years following article publication.</ipd_time_frame>
    <ipd_access_criteria>Researchers who provide a methodologically sound proposal to achieve aims in the approved proposal.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

